PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer

NCT04612530 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions

DEVICE: Irreversible Electroporation (IRE)
DRUG: Nivolumab
DRUG: Toll-Like Receptor 9

Sponsor

Amsterdam UMC, location VUmc